Filing Flows › Zomedica (ZOMDF) › Q3 2026 › vs Q2 2026
Zomedica (ZOMDF) Q3 2026 vs Q2 2026 (quarter over quarter)
Zomedica's revenue rose $387K (+4%) from $9.5M in Q2 2026 to $9.9M in Q3 2026. The biggest changes: Capital +$169K (+9%); Consumables +$145K (+2%); Other +$71K (+158%).
Zomedica, Q3 2026: revenue $9.9M (+22% year over year), operating margin -34.6%, net loss $3.2M, operating cash flow −$2.8M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Consumables | $6.8M | $6.6M | $145K | +2% |
| Capital | $2.0M | $1.8M | $169K | +9% |
| Engineering | $981K | $979K | $2K | +0.2% |
| Other | $116K | $45K | $71K | +158% |
| Revenue | $9.9M | $9.5M | $387K | +4% |
| Other income, net | $268K | $344K | −$76K | -22% |
| Net loss | $3.2M | $3.8M | −$599K | -16% |
| Costs & expenses | $13.3M | $13.6M | −$288K | -2% |
| Operating costs | $13.3M | $13.6M | −$271K | -2% |
| Income tax | $9K | $26K | −$17K | -65% |
| Cost of revenue | $3.9M | $3.5M | $384K | +11% |
| Research & development | $1.2M | $1.1M | $134K | +13% |
| Sales & marketing | $3.6M | $3.7M | −$115K | -3% |
| General & admin | $4.7M | $5.4M | −$674K | -13% |
| Operating cash sources | $4.6M | $4.4M | $199K | +5% |
| Depreciation & amortization | $1.8M | $1.8M | −$19K | -1% |
| Cash used in operations | $2.8M | $2.6M | $218K | +9% |
| Net loss absorbed | $3.2M | $3.8M | −$599K | -16% |
| Working capital & other | $1.4M | $698K | $729K | +104% |
Questions
How much did Zomedica's revenue grow quarter over quarter in Q3 2026?
Zomedica's revenue rose $387K (+4%) from $9.5M in Q2 2026 to $9.9M in Q3 2026.
What drove Zomedica's revenue change in Q3 2026?
Capital +$169K (+9%); Consumables +$145K (+2%); Other +$71K (+158%).